Yonhap Infomax NewsHanmi Pharmaceutical's board replaces CEO Park Jae-hyun and four directors, appointing HB Investment's Hwang Sang-yeon as new chief candidate amid ongoing management dispute between major shareholders and professional managers over company direction and founding principles.
#YonhapInfomax #HanmiPharmaceutical #CeoReplacement #HwangSangyeon #ManagementDispute #BoardRestructuring #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=109619
#YonhapInfomax #HanmiPharmaceutical #CeoReplacement #HwangSangyeon #ManagementDispute #BoardRestructuring #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=109619
Hanmi Pharmaceutical Replaces CEO Park Jae-hyun, Names Hwang Sang-yeon as New Chief Candidate
Hanmi Pharmaceutical's board replaces CEO Park Jae-hyun and four directors, appointing HB Investment's Hwang Sang-yeon as new chief candidate amid ongoing management dispute between major shareholders and professional managers over company direction and founding principles.